Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment

Eli Lilly announced on Wednesday it had found proof of concept data from an interim analysis of the BLAZE-1 clinical trial that showed a reduced rate of hospitalization for coronavirus patients treated with its neutralizing antibody drug.